Live tape
Top 8, mentions 7d14,338NVDA4,854 mentions▲ +0.04GOOGL2,061 mentions▲ +0.04SPY1,736 mentions▲ +0.06QQQ1,554 mentions▲ +0.05AMD1,212 mentions▲ +0.08SPCX1,106 mentions▲ +0.05TSLA954 mentions▲ +0.04SNDK861 mentions▲ +0.05

Equity · Healthcare

VIR

NASDAQ

Vir Biotechnology (VIR)

9.43 USD +0.32% vs prior close
Vir Biotechnology, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.

Track this symbol on TradingView
Market cap
1.6B USD
Revenue, year to Dec 2025
68.6M USD
EPS, diluted, year to Dec 2025
−3.16 USD
52-week range
4.27 USD – 11.70 USD
Avg volume
367.3K

as of Jul 17, 2026

Have Vir Biotechnology (VIR) insiders bought or sold shares recently?

In the 90 days to 10 Nov 2026, Vir Biotechnology insiders reported 2 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 6 Oct 2025, show no open-market purchase.

Form 4, 90 days to 10 Nov 2026, newest reported trade 3 Nov 2026

0buys
2sells
$42Knet sold
1other filings
Have Vir Biotechnology (VIR) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
03 Nov 2026de Verneuil VaninaEVP, General Counsel, Corp SecSell2,40727K USD
02 Nov 2026de Verneuil VaninaEVP, General Counsel, Corp SecSell1,34315K USD
Sold2 open-market sales3,750$42K
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
Have Vir Biotechnology (VIR) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
27 Oct 2026Topalian Suzanne LouiseDirectorAward12,731

Which funds hold Vir Biotechnology (VIR)?

8 of the 45 institutional funds we track reported a Vir Biotechnology position for the quarter ended 30 Jun 2026 — a combined 101.7M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold Vir Biotechnology (VIR)?
FundPositionSharesValueShares q/q
Point72 Asset ManagementAdded5,666,82157.7M USD+190.3%
Two Sigma InvestmentsHeld (±25%)1,110,22711.3M USD−22.9%
Renaissance TechnologiesAdded1,016,86410.4M USD+33.6%
Citadel AdvisorsTrimmed991,33710.1M USD−52.8%
AQR Capital ManagementHeld (±25%)581,4165.9M USD+2.7%
D. E. Shaw & Co.Trimmed416,4034.2M USD−49.1%
Man GroupHeld (±25%)150,6881.5M USD−15.3%
Millennium ManagementTrimmed47,993489K USD−90.2%
Tudor Investment CorpExited

What has been filed or recorded for Vir Biotechnology (VIR)?

The filings we hold for Vir Biotechnology, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 06 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Vir Biotechnology (VIR)?
And
06 Oct 2026Fails to deliverShares failed to deliver84,198 shares992K USD notional · 0.050% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.57 USD
30 Sep 2026FinancialsTotal assets1.1B USDat period end
30 Sep 2026FinancialsTotal equity896.0M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS 0.47 USDRevenue $239M
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.85 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −3.16 USDRevenue $69M
31 Dec 2025FinancialsRevenue68.6M USDfiscal year
31 Dec 2025FinancialsNet income−438.0M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−3.16 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −1.17 USDRevenue $0M
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.80 USDRevenue $1M
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.88 USDRevenue $3M
31 Dec 2024Annual reportFY 2024 reportedEPS −3.83 USDRevenue $74M

What do people ask about Vir Biotechnology (VIR)?

From live data
What is Vir Biotechnology’s market cap?1.6B

Vir Biotechnology is worth 1.6B USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

What is Vir Biotechnology’s revenue?68.6M

Vir Biotechnology reported revenue of 68.6M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Vir Biotechnology insiders bought or sold shares recently?2 sales

In the 90 days to 10 Nov 2026, Vir Biotechnology insiders reported 2 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 6 Oct 2025, show no open-market purchase. A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders

Which funds own Vir Biotechnology?8 of 45

8 of the 45 funds we track reported a Vir Biotechnology position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Point72 Asset Management, Two Sigma Investments and Renaissance Technologies. See Funds

When did Vir Biotechnology last report earnings?−0.57

Vir Biotechnology last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.57 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings